2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

4999 CRISPR-Cas9 screening identifies KIT as a therapeutically actionable driver of venetoclax resistance in t(8;21) AML

Yu Liu, Qianqian Huang2, Tong Zhou3, Wenbing Liu4, Chengcai Guo5, Min Wang, PhD6, Jianxiang Wang Sr, MD, PhD7, Shaowei Qiu, MD8
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China, Tianjin, China

Venetoclax-based regimens have transformed the therapeutic landscape of acute myeloid leukemia (AML); however, accumulating clinical evidence indicates that a substantial subset of t(8;21) AML patients exhibit primary resistance to venetoclax monotherapy, highlighting an urgent need to dissect the underlying mechanisms and devise effective intervention strategies. In this study, we systematically interrogated the intrinsic resistance landscape of t(8;21) AML to venetoclax and sought to identify actionable targets capable of restoring therapeutic sensitivity.

We first evaluated venetoclax sensitivity across a panel of AML cell lines representing distinct molecular subtypes. Kasumi-1 and SKNO-1, both harboring the t(8;21) translocation, exhibited marked resistance relative to other common AML cell lines. Consistently, venetoclax treatment failed to reduce leukemic burden and conferred no survival advantage over vehicle controls in AML1-ETO (AE9a) and AML1-ETO C-KITmut (AE C-KITmut) murine models, collectively confirming the refractory nature of t(8;21) AML to venetoclax both in vitro and in vivo.

To uncover the mechanistic drivers of this resistance, we constructed a customized sgRNA library enriched for genes transcriptionally regulated by AML1-ETO and performed an unbiased CRISPR-Cas9 screen in Kasumi-1 cells. Following venetoclax treatment, cells were sorted into Annexin-V???? and Annexin-V??? populations; untreated controls were used to exclude genes that intrinsically affect apoptosis, enabling the specific identification of venetoclax resistance-associated genes. Among the top-ranking candidates, KIT and HDAC3 emerged as leading hits; HDAC3 served as a positive control given its well-documented association with venetoclax resistance, thereby validating the fidelity of our screening approach. Genetic ablation of KIT in Kasumi-1 and SKNO-1 cells significantly resensitized both cell lines to venetoclax in vitro. This finding was further corroborated in NSG xenograft models, where KIT-deficient Kasumi-1 cells were profoundly resensitized to venetoclax, leading to significantly reduced tumor burden and extended recipient survival relative to controls, thus confirming the critical role of KIT in venetoclax resistance in vivo.

To evaluate the clinical relevance of our findings, we performed longitudinal whole-exome sequencing (WES) on serial bone marrow samples from venetoclax-resistant t(8;21) AML patients. Notably, KIT-D816 mutations were consistently detected throughout the treatment course, suggesting their role as drivers of venetoclax resistance. Furthermore, co-treatment with the KIT-D816-specific inhibitor avapritinib could partially reverse venetoclax resistance, and similar resensitization was achieved with multi-kinase inhibitors targeting the KIT pathway, including sorafenib and dasatinib, underscoring the therapeutic potential of KIT-directed intervention.

Collectively, our study systematically characterizes venetoclax resistance in t(8;21) AML and establishes KIT signaling as a critical driver of venetoclax resistance. Through unbiased CRISPR screening, we demonstrate that KIT contributes to venetoclax refractoriness, with persistent KIT-D816 mutations serving as potential drivers in the clinical setting. Importantly, KIT-directed pharmacological inhibition, whether mutation-specific or pathway-level, can partially restore venetoclax sensitivity, offering a rational combinatorial strategy. These findings advance our understanding of t(8;21) AML-specific resistance mechanisms to venetoclax and provide potential therapeutic strategies to improve outcomes for these patients.

Yu Liu: No relevant conflicts of interest to declare.